GFR-话题@MedSci

#GFR#

483篇内容 | 2458人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1534598, encodeId=209d153459865, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=新型VEGFR抑制剂Fruquintinib治疗转移性结直肠癌：全球III期试验已经开始, objectType=article, longId=292042, objectId=cf0429204269, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cf0429204269, replyNumber=0, likeNumber=64, createdTime=2021-12-18, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cf0429204269, moduleTitle=新型VEGFR抑制剂Fruquintinib治疗转移性结直肠癌：全球III期试验已经开始, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=cf0429204269)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534600, encodeId=de57153460082, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=BMC Cancer：EGFR 19外显子缺失插入突变患者一代EGFR-TKI治疗应答较好，获得T790M突变后奥希替尼治疗同样应答较好, objectType=article, longId=292019, objectId=0498292019ed, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0498292019ed, replyNumber=0, likeNumber=100, createdTime=2021-12-18, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0498292019ed, moduleTitle=BMC Cancer：EGFR 19外显子缺失插入突变患者一代EGFR-TKI治疗应答较好，获得T790M突变后奥希替尼治疗同样应答较好, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0498292019ed)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534599, encodeId=947415345990c, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=Thorac Cancer：EGFR突变肺癌EGFR-TKIs治疗进展后应用免疫检查点抑制剂治疗的疗效, objectType=article, longId=291958, objectId=864c29195801, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=864c29195801, replyNumber=0, likeNumber=93, createdTime=2021-12-17, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=864c29195801, moduleTitle=Thorac Cancer：EGFR突变肺癌EGFR-TKIs治疗进展后应用免疫检查点抑制剂治疗的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=864c29195801)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534597, encodeId=81a9153459eed, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=APOLLO研究荣登JTO！中国原研三代EGFR-TKI阿美替尼以优异疗效数据惠及更多中国患者, objectType=article, longId=291811, objectId=3a262918115e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3a262918115e, replyNumber=0, likeNumber=56, createdTime=2021-12-16, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3a262918115e, moduleTitle=APOLLO研究荣登JTO！中国原研三代EGFR-TKI阿美替尼以优异疗效数据惠及更多中国患者, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3a262918115e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534596, encodeId=433615345961a, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=Alzheimer Dementia：PDGFRβ与阿尔兹海默症的生物标志物有关, objectType=article, longId=264967, objectId=206926496e4f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=206926496e4f, replyNumber=0, likeNumber=66, createdTime=2021-12-12, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=206926496e4f, moduleTitle=Alzheimer Dementia：PDGFRβ与阿尔兹海默症的生物标志物有关, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=206926496e4f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534595, encodeId=ae40153459575, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=Front Oncol：EGFR突变NSCLC患者使用EGFR-TKI进展后一线使用免疫治疗可能可改善患者预后, objectType=article, longId=221235, objectId=6ad622123581, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6ad622123581, replyNumber=0, likeNumber=74, createdTime=2021-11-30, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6ad622123581, moduleTitle=Front Oncol：EGFR突变NSCLC患者使用EGFR-TKI进展后一线使用免疫治疗可能可改善患者预后, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6ad622123581)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534594, encodeId=acfe153459492, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=J Thorac Oncol：Aumolertinib(HS-10296)治疗EGFR-T790M+晚期NSCLC患者的疗效和安全性：APOLLO研究, objectType=article, longId=221184, objectId=7716221184e3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7716221184e3, replyNumber=0, likeNumber=56, createdTime=2021-11-29, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7716221184e3, moduleTitle=J Thorac Oncol：Aumolertinib(HS-10296)治疗EGFR-T790M+晚期NSCLC患者的疗效和安全性：APOLLO研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7716221184e3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534593, encodeId=0d7d1534593c3, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=APOLLO研究：Aumolertinib在中国获批用于EGFR T790M阳性NSCLC患者, objectType=article, longId=221110, objectId=ba8922111014, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ba8922111014, replyNumber=0, likeNumber=64, createdTime=2021-11-28, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ba8922111014, moduleTitle=APOLLO研究：Aumolertinib在中国获批用于EGFR T790M阳性NSCLC患者, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ba8922111014)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534592, encodeId=b7bb153459279, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=Thorac Cancer：伴有EGFR-T790M突变的NSCLC患者，后续奥希替尼不同顺序治疗生存对比, objectType=article, longId=220998, objectId=36ac220998de, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=36ac220998de, replyNumber=0, likeNumber=65, createdTime=2021-11-26, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=36ac220998de, moduleTitle=Thorac Cancer：伴有EGFR-T790M突变的NSCLC患者，后续奥希替尼不同顺序治疗生存对比, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=36ac220998de)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534591, encodeId=76c2153459149, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=Thorac Cancer： EGFR-TKIs提前应用可改善不可切除的III期EGFR突变肺腺癌的预后, objectType=article, longId=220997, objectId=b57822099e0a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b57822099e0a, replyNumber=0, likeNumber=75, createdTime=2021-11-26, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b57822099e0a, moduleTitle=Thorac Cancer： EGFR-TKIs提前应用可改善不可切除的III期EGFR突变肺腺癌的预后, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b57822099e0a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534590, encodeId=86261534590cc, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=Clinical Lung Cancer：HER2基因改变在EGFR突变型非小细胞肺癌（NSCLC）中的作用, objectType=article, longId=220913, objectId=6a77220913bb, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6a77220913bb, replyNumber=0, likeNumber=73, createdTime=2021-11-25, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6a77220913bb, moduleTitle=Clinical Lung Cancer：HER2基因改变在EGFR突变型非小细胞肺癌（NSCLC）中的作用, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6a77220913bb)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534589, encodeId=84c815345897c, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=Thorac Cancer：真实世界中dacomitinib（达可替尼）治疗伴有脑转移的EGFR突变阳性NSCLC患者的疗效, objectType=article, longId=220889, objectId=d4ae2208892d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d4ae2208892d, replyNumber=0, likeNumber=45, createdTime=2021-11-25, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d4ae2208892d, moduleTitle=Thorac Cancer：真实世界中dacomitinib（达可替尼）治疗伴有脑转移的EGFR突变阳性NSCLC患者的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d4ae2208892d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534588, encodeId=15691534588c3, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=Front Oncol：Afatinib（阿法替尼）治疗EGFR突变阳性的局部晚期或转移性非小细胞肺癌（NSCLC）的疗效：来自3个IIIb期研究的合并分析, objectType=article, longId=220865, objectId=1061220865c1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1061220865c1, replyNumber=0, likeNumber=27, createdTime=2021-11-24, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1061220865c1, moduleTitle=Front Oncol：Afatinib（阿法替尼）治疗EGFR突变阳性的局部晚期或转移性非小细胞肺癌（NSCLC）的疗效：来自3个IIIb期研究的合并分析, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1061220865c1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534587, encodeId=32e8153458ebb, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=非小细胞肺癌EGFR基因突变检测技术进展, objectType=article, longId=220729, objectId=914c220e29fc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=914c220e29fc, replyNumber=0, likeNumber=78, createdTime=2021-11-23, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=914c220e29fc, moduleTitle=非小细胞肺癌EGFR基因突变检测技术进展, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=914c220e29fc)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534586, encodeId=732b153458650, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=A+T在EGFR突变阳性NSCLC的治疗新格局, objectType=article, longId=220696, objectId=2d11220696ee, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2d11220696ee, replyNumber=0, likeNumber=44, createdTime=2021-11-22, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2d11220696ee, moduleTitle=A+T在EGFR突变阳性NSCLC的治疗新格局, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2d11220696ee)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534585, encodeId=0e5015345856e, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=解毒复正汤联合EGFR-TKIs对老年晚期肺癌患者的临床疗效观察, objectType=article, longId=220637, objectId=011e22063e38, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=011e22063e38, replyNumber=0, likeNumber=71, createdTime=2021-11-21, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=011e22063e38, moduleTitle=解毒复正汤联合EGFR-TKIs对老年晚期肺癌患者的临床疗效观察, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=011e22063e38)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534584, encodeId=0f55153458403, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=J Thorac Oncol：ADAURA研究：IB-IIIA期EGFR突变阳性NSCLC切除术后使用奥希替尼辅助治疗改善患者DFS，无论是否接受辅助化疗, objectType=article, longId=220083, objectId=ae6a2200837d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ae6a2200837d, replyNumber=0, likeNumber=66, createdTime=2021-11-12, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ae6a2200837d, moduleTitle=J Thorac Oncol：ADAURA研究：IB-IIIA期EGFR突变阳性NSCLC切除术后使用奥希替尼辅助治疗改善患者DFS，无论是否接受辅助化疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ae6a2200837d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534583, encodeId=621715345833c, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=Clin Cancer Res：第三代EGFR-TKI Abvertinib治疗EGFR T790M+ NSCLC的活性和安全性, objectType=article, longId=220039, objectId=bb122200396e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bb122200396e, replyNumber=0, likeNumber=118, createdTime=2021-11-11, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bb122200396e, moduleTitle=Clin Cancer Res：第三代EGFR-TKI Abvertinib治疗EGFR T790M+ NSCLC的活性和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=bb122200396e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534582, encodeId=d63d1534582e2, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=LDE：在DAPA-CKD试验中，通过蛋白尿和eGFR斜率预测治疗反应, objectType=article, longId=219695, objectId=e984219695dd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e984219695dd, replyNumber=0, likeNumber=95, createdTime=2021-11-04, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e984219695dd, moduleTitle=LDE：在DAPA-CKD试验中，通过蛋白尿和eGFR斜率预测治疗反应, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e984219695dd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534581, encodeId=818b1534581a4, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=Front Oncol：左侧RAS/BRAF野生型转移性结直肠癌(mCRC)患者一线抗表皮生长因子受体(EGFR)为基础治疗后后续维持治疗管理, objectType=article, longId=219570, objectId=1d282195e0e7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1d282195e0e7, replyNumber=0, likeNumber=27, createdTime=2021-11-02, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1d282195e0e7, moduleTitle=Front Oncol：左侧RAS/BRAF野生型转移性结直肠癌(mCRC)患者一线抗表皮生长因子受体(EGFR)为基础治疗后后续维持治疗管理, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1d282195e0e7)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

GFR

2020-05-29

liuyiping (审核中...)

前往app查看评论内容

#GFR#

新型VEGFR抑制剂Fruquintinib治疗转移性结直肠癌：全球III期试验已经开始

2021-12-18

liuyiping (审核中...)

前往app查看评论内容

#GFR#

BMC Cancer：EGFR 19外显子缺失插入突变患者一代EGFR-TKI治疗应答较好，获得T790M突变后奥希替尼治疗同样应答较好

2021-12-18

liuyiping (审核中...)

前往app查看评论内容

#GFR#

Thorac Cancer：EGFR突变肺癌EGFR-TKIs治疗进展后应用免疫检查点抑制剂治疗的疗效

2021-12-17

liuyiping (审核中...)

前往app查看评论内容

#GFR#

APOLLO研究荣登JTO！中国原研三代EGFR-TKI阿美替尼以优异疗效数据惠及更多中国患者

2021-12-16

liuyiping (审核中...)

前往app查看评论内容

#GFR#

Alzheimer Dementia：PDGFRβ与阿尔兹海默症的生物标志物有关

2021-12-12

liuyiping (审核中...)

前往app查看评论内容

#GFR#

Front Oncol：EGFR突变NSCLC患者使用EGFR-TKI进展后一线使用免疫治疗可能可改善患者预后

2021-11-30

智智灵药 (审核中...)

前往app查看评论内容

#GFR#

J Thorac Oncol：Aumolertinib(HS-10296)治疗EGFR-T790M+晚期NSCLC患者的疗效和安全性：APOLLO研究

2021-11-29

liuyiping (审核中...)

前往app查看评论内容

#GFR#

APOLLO研究：Aumolertinib在中国获批用于EGFR T790M阳性NSCLC患者

2021-11-28

liuyiping (审核中...)

前往app查看评论内容

#GFR#

Thorac Cancer：伴有EGFR-T790M突变的NSCLC患者，后续奥希替尼不同顺序治疗生存对比

2021-11-26

liuyiping (审核中...)

前往app查看评论内容

#GFR#

Thorac Cancer： EGFR-TKIs提前应用可改善不可切除的III期EGFR突变肺腺癌的预后

2021-11-26

liuyiping (审核中...)

前往app查看评论内容

#GFR#

Clinical Lung Cancer：HER2基因改变在EGFR突变型非小细胞肺癌（NSCLC）中的作用

2021-11-25

liuyiping (审核中...)

前往app查看评论内容

#GFR#

Thorac Cancer：真实世界中dacomitinib（达可替尼）治疗伴有脑转移的EGFR突变阳性NSCLC患者的疗效

2021-11-25

liuyiping (审核中...)

前往app查看评论内容

#GFR#

Front Oncol：Afatinib（阿法替尼）治疗EGFR突变阳性的局部晚期或转移性非小细胞肺癌（NSCLC）的疗效：来自3个IIIb期研究的合并分析

2021-11-24

liuyiping (审核中...)

前往app查看评论内容

#GFR#

非小细胞肺癌EGFR基因突变检测技术进展

2021-11-23

liuyiping (审核中...)

前往app查看评论内容

#GFR#

A+T在EGFR突变阳性NSCLC的治疗新格局

2021-11-22

liuyiping (审核中...)

前往app查看评论内容

#GFR#

解毒复正汤联合EGFR-TKIs对老年晚期肺癌患者的临床疗效观察

2021-11-21

liuyiping (审核中...)

前往app查看评论内容

#GFR#

J Thorac Oncol：ADAURA研究：IB-IIIA期EGFR突变阳性NSCLC切除术后使用奥希替尼辅助治疗改善患者DFS，无论是否接受辅助化疗

2021-11-12

liuyiping (审核中...)

前往app查看评论内容

#GFR#

Clin Cancer Res：第三代EGFR-TKI Abvertinib治疗EGFR T790M+ NSCLC的活性和安全性

2021-11-11

liuyiping (审核中...)

前往app查看评论内容

#GFR#

LDE：在DAPA-CKD试验中，通过蛋白尿和eGFR斜率预测治疗反应

2021-11-04

liuyiping (审核中...)

前往app查看评论内容

#GFR#

Front Oncol：左侧RAS/BRAF野生型转移性结直肠癌(mCRC)患者一线抗表皮生长因子受体(EGFR)为基础治疗后后续维持治疗管理

2021-11-02

科室
- - 订阅+
  - 更多科室
工具
服务